PYXS | Pyxis Oncology, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.0500 - 1.1050
52 Week Range	0.9850 - 6.18
Beta	1.37
Implied Volatility	1,501.27%
IV Rank	56.36%
Day's Volume	359,834
Average Volume	613,900
Shares Outstanding	61,590,416
Market Cap	65,285,841
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-10-08

Valuation
Profitability
Growth
Health
P/E Ratio	-0.80
Forward P/E Ratio	-1.24
EPS	-1.32
1YR Price Target	9.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	54
Country	USA
Website	PYXS

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.

PYXS's peers: DRUG, PYPD, ZURA, EFTR, CYTO, ELEV, MREO, PDSB, XFOR, CRVS, TERN, ZVSA, OCEA, ICVX, INZY, HOOK, VTVT, CDIO

*Chart delayed

Analyzing fundamentals for PYXS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PYXS Fundamentals page.

Watching at PYXS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PYXS Technicals page.